Influence of dabigatran and rivaroxaban on routine coagulation assays
نویسندگان
چکیده
منابع مشابه
What is the effect of rivaroxaban on routine coagulation tests?
A 78-year-old female presents to the emergency department with a traumatic hip fracture. Her past medical history is significant for atrial fibrillation for which she receives rivaroxaban 20 mg daily. Her dose was last taken 12 hours ago. Routine bloodwork conducted in the emergency department shows prothrombin time, international normalized ratio, and activated partial thromboplastin time with...
متن کاملEffects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
INTRODUCTION Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary but the dose-dependent effects on common reagents and assay procedures are largely unknown. OBJECTIVES To investigate the effect of rivaroxaban on commonly used coagulation assays. MATERIALS AND METHODS Rivaroxaban was add...
متن کاملEffects of Rivaroxaban on Coagulation Assays in Patients with Small Pulmonary Embolism and Deep Vein Thrombosis in Relation to Body Mass Index
Introduction: Rivaroxaban is a new anticoagulant medication for pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT). There are limited data on the effect of body mass index (BMI) on the pharmacokinetics of rivaroxaban. This study aimed to assess the effect of rivaroxaban on coagulation assays in relation to BMI in PTE and DVT patients. Materials and Met...
متن کاملEffects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Dabigatran is an oral, reversible thrombin inhibitor that has shown promising results in large clinical trials. Laboratory monitoring is not needed but the effects on common coagulation assays are incompletely known. Dabigatran was added to plasma from healthy subjects in the concentration range 0-1,000 μg/l and analysed using several reagents for activated thromboplastin time (APTT), prothromb...
متن کاملDabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
BACKGROUND Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the kidneys. Their use in dialysis patients is discouraged because these drugs can bioaccumulate to precipitate inadvertent bleeding. We wanted to determine whether prescription of dabigatran or rivaroxaban was occurring in the dialysis population and whether these practices were safe. METHODS AND RE...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Thrombosis and Haemostasis
سال: 2015
ISSN: 0340-6245,2567-689X
DOI: 10.1160/th14-02-0161